The number of tumors in the colon was significantly reduced in the GLB and NLRP3-KO groups compared to the CTRL cohort (Figure 3D,F), suggesting that GLB treatment and NLRP3 deficiency had suppressed the development of colorectal tumors associated with colitis. This evidence concerns the gene NLRP3 and colitis.